THREE BALA PLAZA EAST. SUITE 506, BALA CYNWYD, PA
Reports Fourth Quarter and Full Year 2025 Financial Results
Investor Presentation
Larimar Therapeutics Enters Underwriting Agreement for 20M Shares
Larimar Therapeutics Enters Exchange Agreement for Preferred Stock
FY 2025
Q3
Q2
Q1
FY 2024
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(5)
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Definitive Proxy Statement
PRE 14A
Additional Proxy Materials
Statement of Changes in Beneficial Ownership
Amended Schedule 13D - Ownership Report
Amended Schedule 13G - Ownership Report